

Model:

Diameter of balloon (mm)	Effective length of balloon (mm)					
	10	15	17	20	26	30
2.00	G2.00-10	G2.00-15	G2.00-17	G2.00-20	G2.00-26	G2.00-30
2.50	G2.50-10	G2.50-15	G2.50-17	G2.50-20	G2.50-26	G2.50-30
2.75	G2.75-10	G2.75-15	G2.75-17	G2.75-20	G2.75-26	G2.75-30
3.00	G3.00-10	G3.00-15	G3.00-17	G3.00-20	G3.00-26	G3.00-30
3.50	G3.50-10	G3.50-15	G3.50-17	G3.50-20	G3.50-26	G3.50-30
4.00	G4.00-10	G4.00-15	G4.00-17	G4.00-20	G4.00-26	G4.00-30

Compliance table:

Pressure (atm)	Balloon length (mm)					
	2.00	2.50	2.75	3.00	3.50	4.00
2	1.87	2.36	2.59	2.82	3.29	3.77
4	1.94	2.43	2.67	2.91	3.39	3.89
6	2.00	2.50	2.75	3.00	3.50	4.00
8Nominal pressure	2.06	2.57	2.83	3.09	3.61	4.11
10	2.13	2.64	2.91	3.18	3.71	4.23
12	2.19	2.71	2.98	3.27	3.82	4.34
14Rated bursting pressure	2.25	2.78	3.06	3.36	3.92	4.45
16	2.32	2.85	3.14	3.45	4.03	4.57
18	2.38	2.92	3.22	3.54	4.14	4.68


Flowty™

Drug-eluting PTCA balloon dilatation catheter




Pure matrix,
crystal delivery

Novel needle shaped PTX microparticles



● **Primary endpoint: Lumen loss in target lesions during later period at ninth month.**




211 patients with coronary stent restenosis, coronary angiography and clinical follow-up observations were performed at ninth month after the operation:

	Flowty™	SeQuent® Please	P value
Preoperative target lesion stenosis degree (%)	67.65±16.56	66.76±13.78	0.657
Restenosis within the target lesion segment after 9 months (%)	10.34	10.58	0.858
Target lesion failure rate in 9 months after operation (%)	4.76	4.72	0.953
Incidence of thrombotic events (%)	0.95	0.94	0.945

Conclusion

There is no statistical difference between Flowty™ and the control group, and it has good safety and effectiveness.

● **Outer diameter lower than the competition**



● **Pharmacokinetic data shows high Concentration of paclitaxel in tissue and sustained therapeutic effect**

